State of Tennessee Treasury Department Has $14.61 Million Holdings in Becton Dickinson and Co (NYSE:BDX)
State of Tennessee Treasury Department cut its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 66.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 63,588 shares of the medical instruments supplier’s stock after selling 125,128 shares during the quarter. State of Tennessee Treasury Department’s holdings in Becton Dickinson and were worth $14,611,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Ascent Wealth Partners LLC raised its stake in shares of Becton Dickinson and by 1.3% in the 1st quarter. Ascent Wealth Partners LLC now owns 30,782 shares of the medical instruments supplier’s stock valued at $7,073,000 after acquiring an additional 389 shares in the last quarter. Colony Group LLC increased its position in Becton Dickinson and by 1.8% in the 1st quarter. Colony Group LLC now owns 26,298 shares of the medical instruments supplier’s stock worth $6,043,000 after buying an additional 453 shares during the period. KBC Group NV grew its holdings in shares of Becton Dickinson and by 29.1% during the 4th quarter. KBC Group NV now owns 109,904 shares of the medical instruments supplier’s stock worth $29,891,000 after purchasing an additional 24,750 shares in the last quarter. Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of Becton Dickinson and by 47.0% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 35,344 shares of the medical instruments supplier’s stock worth $9,613,000 after purchasing an additional 11,300 shares in the last quarter. Finally, Kidder Stephen W grew its holdings in shares of Becton Dickinson and by 12.0% during the 1st quarter. Kidder Stephen W now owns 17,270 shares of the medical instruments supplier’s stock worth $3,968,000 after purchasing an additional 1,856 shares in the last quarter. Hedge funds and other institutional investors own 85.78% of the company’s stock.
In other news, EVP Patrick Kaltenbach sold 1,049 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $243.20, for a total transaction of $255,116.80. Following the transaction, the executive vice president now owns 12,661 shares in the company, valued at $3,079,155.20. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.12% of the stock is currently owned by company insiders.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.23. The firm had revenue of $4.25 billion for the quarter, compared to analyst estimates of $4.10 billion. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.59 earnings per share. As a group, sell-side analysts anticipate that Becton Dickinson and Co will post 10.42 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Monday, June 8th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.37%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.05%.
BDX has been the topic of several recent analyst reports. Barclays reaffirmed a “hold” rating and issued a $266.00 price target on shares of Becton Dickinson and in a research note on Tuesday, April 14th. KeyCorp restated a “hold” rating on shares of Becton Dickinson and in a research report on Tuesday, May 12th. TheStreet downgraded Becton Dickinson and from a “b” rating to a “c+” rating in a report on Monday, March 9th. Piper Sandler upped their price objective on Becton Dickinson and from $286.00 to $296.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Finally, Cfra lowered their price target on Becton Dickinson and from $285.00 to $278.00 and set a “hold” rating for the company in a report on Friday, May 8th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have assigned a buy rating to the company’s stock. Becton Dickinson and presently has a consensus rating of “Hold” and a consensus price target of $272.00.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
See Also: What is a stock portfolio tracker?
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.